FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.
What happened
FDA reviewed the company's website in August 2025 and found it offered compounded semaglutide products using the name "Ozempic" and supply periods. FDA said the claims falsely imply the compounded products are the same as the FDA-approved drug Ozempic, making them misbranded.
What FDA found
Website claims called compounded semaglutide "Ozempic," implying it is the same as an FDA-approved drug when it is not.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website's advertising or promotion of compounded semaglutide was false or misleading.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The company introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Cosmo Med Spa to immediately stop using the misleading "Ozempic" claims and respond within 15 working days with the steps taken and documentation to prevent recurrence.
Who should pay attention
- telehealth platforms selling compounded semaglutide
- compounding pharmacies marketing GLP-1 drugs online
- U.S. buyers of compounded semaglutide
This is a summary. Read the original letter on fda.gov.